The identification of therapeutics for NAFLD has also been complicated by the observation that PNPLA3 variants can reduce the efficacy of potential drugs, including the GLP-1 receptor agonist exenatide [35]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.